Egalet is a specialty pharma company focusing on pain management. The Company is developing a pipeline of abuse-resistant opioids that are nearing pivotal testing. Egalet has pioneered one of the world’s first erosion-based delivery technologies to enable the controlled release of drugs through gradual erosion of a tablet and has optimized the abuse deterrent properties that can be applied to a broad range of opioids and non-opioids.
Type
Public
HQ
Wayne, US
Founded
1995
Size (employees)
154 (est)+98%
Website
egalet.com
Egalet was founded in 1995 and is headquartered in Wayne, US
Report incorrect company information

Egalet Office Locations

Egalet has an office in Wayne
Wayne, US (HQ)
460 E Swedesford Rd
Show all (1)
Report incorrect company information

Egalet Financials and Metrics

Egalet Financials

Egalet's revenue was reported to be $16.96 m in FY, 2016 which is a 25.7% decrease from the previous period.
USD

Revenue (Q1, 2018)

6.3 m

Gross profit (Q1, 2018)

4 m

Gross profit margin (Q1, 2018), %

64.6%

Net income (Q1, 2018)

(12.4 m)

EBIT (Q1, 2018)

(13.9 m)

Market capitalization (14-Jun-2018)

25.1 m

Closing share price (14-Jun-2018)

0.5

Cash (31-Mar-2018)

33.7 m
Egalet's current market capitalization is $25.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

1.9 m22.8 m17 m

Revenue growth, %

1089%(26%)

Cost of goods sold

3.3 m3.7 m

Gross profit

19.6 m13.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

805 k959 k1.7 m2.7 m3.5 m4.7 m5.4 m6.3 m6.7 m6.3 m

Cost of goods sold

94 k207 k349 k882 k784 k914 k1.3 m1.1 m1.2 m2.2 m

Gross profit

711 k752 k1.3 m1.8 m2.7 m3.8 m4.1 m5.2 m5.4 m4 m

Gross profit Margin, %

88%78%79%67%77%81%76%83%81%65%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

52.7 m46.7 m44.4 m

Accounts Receivable

1 m295 k1.1 m

Inventories

3.5 m1.3 m2.5 m

Current Assets

55.1 m150.2 m93.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

69.3 m59.7 m53.9 m57.7 m77.2 m34.2 m35 m46.6 m27 m29.9 m37.8 m33.7 m

Accounts Receivable

230 k213 k896 k931 k922 k829 k820 k3.9 m5.4 m5.1 m5.6 m15 m

Inventories

2.6 m3.9 m3.6 m2.1 m1.7 m1.5 m1.5 m1.9 m1.4 m2.1 m

Current Assets

70.4 m61 m69 m114.4 m175.6 m130.4 m108.5 m109.7 m114.9 m97.1 m112.1 m94.7 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(43.2 m)(57.9 m)(90.6 m)

Depreciation and Amortization

641 k3 m4.1 m

Inventories

3.9 m(631 k)(1.2 m)

Accounts Payable

3.3 m1.1 m(2.9 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(24.6 m)(34.7 m)(16.7 m)(33.8 m)(51.2 m)(18.5 m)(42.3 m)(69.3 m)(25.4 m)(51.9 m)(18.9 m)(12.4 m)

Depreciation and Amortization

311 k466 k631 k1.5 m2.3 m822 k1.7 m2.7 m1.4 m2.6 m1.2 m

Inventories

(40 k)(479 k)(144 k)(300 k)95 k350 k189 k(249 k)1.4 m955 k

Accounts Payable

1.5 m334 k(1.2 m)(470 k)(724 k)(695 k)(46 k)373 k4.3 m790 k5.6 m(19 k)
USDY, 2018

Financial Leverage

-3.4 x
Show all financial metrics
Report incorrect company information

Egalet Online and Social Media Presence

Embed Graph
Report incorrect company information

Egalet News and Updates

VC-backed Eloxx Pharmaceuticals names CFO

Israel and Waltham, Massachusetts-based Eloxx Pharmaceuticals Ltd, a developer of treatments that focus on genetic diseases caused by nonsense mutations, has appointed Gregory Weaver as chief financial officer. He is the former CFO at Prometic Life Sciences. The investors included Korea Investment P…
Report incorrect company information